Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 360

1.

Erdheim-Chester disease: Consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era.

Goyal G, Heaney ML, Collin M, Cohen Aubart F, Vaglio A, Durham BH, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen ED, Toyama K, Goodman AM, Hendrie P, Cao XX, Estrada-Veras J, Shpilberg O, Abdo A, Kurokawa M, Dagna L, McClain KL, Mazor RD, Picarsic J, Janku F, Go RS, Haroche J, Diamond E.

Blood. 2020 Mar 18. pii: blood.2019003507. doi: 10.1182/blood.2019003507. [Epub ahead of print]

PMID:
32187362
2.

Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine.

de la Fuente MI, Rosenblum MK, Diamond EL, Tabar VS, Omuro A.

Neurol Neuroimmunol Neuroinflamm. 2020 Mar 2;7(3). pii: e686. doi: 10.1212/NXI.0000000000000686. Print 2020 May. No abstract available.

3.

The unique burden of rare cancer caregiving: caregivers of patients with Erdheim-Chester disease.

Applebaum AJ, Polacek LC, Walsh L, Reiner AS, Lynch K, Benvengo S, Buthorn J, Atkinson TM, Mao JJ, Panageas KS, Diamond EL.

Leuk Lymphoma. 2020 Feb 24:1-12. doi: 10.1080/10428194.2020.1719090. [Epub ahead of print]

PMID:
32090658
4.

Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers.

Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, Hyman DM.

Cancer Discov. 2020 Feb 6. pii: CD-19-1265. doi: 10.1158/2159-8290.CD-19-1265. [Epub ahead of print]

5.

Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.

Bhatia A, Hatzoglou V, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Yabe M, Petrova-Drus K, Panageas KS, Reiner A, Rosenblum M, Diamond EL.

Neuro Oncol. 2020 Jan 17. pii: noaa008. doi: 10.1093/neuonc/noaa008. [Epub ahead of print]

PMID:
31950179
6.

The coming of age of Langerhans cell histiocytosis.

Allen CE, Beverley PCL, Collin M, Diamond EL, Egeler RM, Ginhoux F, Glass C, Minkov M, Rollins BJ, van Halteren A.

Nat Immunol. 2020 Jan;21(1):1-7. doi: 10.1038/s41590-019-0558-z. No abstract available.

PMID:
31831887
7.

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.

Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, Pannecoucke E, Lu SX, Pastore A, Yoshimi A, Mandelker D, Ceyhan-Birsoy O, Ulaner GA, Walsh M, Yabe M, Petrova-Drus K, Arcila ME, Ladanyi M, Solit DB, Berger MF, Hyman DM, Lacouture ME, Erickson C, Saganty R, Ki M, Dunkel IJ, Santa-María López V, Mora J, Haroche J, Emile JF, Decaux O, Geissmann F, Savvides SN, Drilon A, Diamond EL, Abdel-Wahab O.

Nat Med. 2019 Dec;25(12):1839-1842. doi: 10.1038/s41591-019-0653-6. Epub 2019 Nov 25.

PMID:
31768065
8.

BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.

Picarsic J, Pysher T, Zhou H, Fluchel M, Pettit T, Whitehead M, Surrey LF, Harding B, Goldstein G, Fellig Y, Weintraub M, Mobley BC, Sharples PM, Sulis ML, Diamond EL, Jaffe R, Shekdar K, Santi M.

Acta Neuropathol Commun. 2019 Nov 4;7(1):168. doi: 10.1186/s40478-019-0811-6.

9.

Cobimetinib-induced "dropped head syndrome" and subsequent disease management in an Erdheim-Chester patient.

King AC, Diamond EL, Orozco JS, Morse HR, Ouyang LL, Schöder H, Rampal RK.

Clin Case Rep. 2019 Sep 10;7(10):1989-1993. doi: 10.1002/ccr3.2297. eCollection 2019 Oct.

10.

Correction to: Sequencing and curation strategies for identifying candidate glioblastoma treatments.

Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang X, Vacic V, Bergmann EA, Moore Vogel JL, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB.

BMC Med Genomics. 2019 Aug 2;12(1):114. doi: 10.1186/s12920-019-0563-y.

11.

Molecular Diagnosis of Vaginitis: Comparing Quantitative PCR and Microbiome Profiling Approaches to Current Microscopy Scoring.

Lynch T, Peirano G, Lloyd T, Read R, Carter J, Chu A, Shaman JA, Jarvis JP, Diamond E, Ijaz UZ, Church D.

J Clin Microbiol. 2019 Aug 26;57(9). pii: e00300-19. doi: 10.1128/JCM.00300-19. Print 2019 Sep.

12.

Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas.

Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, Arnold AG, Stadler ZK, Mandelker D, Goldberg ME, Chmielecki J, Pourmaleki M, Ogilvie SQ, Chavan SS, McKeown AT, Manne M, Hyde A, Beal K, Yang TJ, Nolan CP, Pentsova E, Omuro A, Gavrilovic IT, Kaley TJ, Diamond EL, Stone JB, Grommes C, Boire A, Daras M, Piotrowski AF, Miller AM, Gutin PH, Chan TA, Tabar VS, Brennan CW, Rosenblum M, DeAngelis LM, Mellinghoff IK, Taylor BS.

Clin Cancer Res. 2019 Sep 15;25(18):5537-5547. doi: 10.1158/1078-0432.CCR-19-0032. Epub 2019 Jul 1.

13.

School-wide implementation of positive behavioral interventions and supports in an alternative school setting: A case study.

Griffiths AJ, Diamond EL, Alsip J, Furlong M, Morrison G, Do B.

J Community Psychol. 2019 Jul;47(6):1493-1513. doi: 10.1002/jcop.22203. Epub 2019 Jun 18.

PMID:
31212369
14.

Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1.

Razanamahery J, Diamond EL, Cohen-Aubart F, Plate KH, Lourida G, Charlotte F, Hélias-Rodzewicz Z, Goyal G, Go RS, Dogan A, Abdel-Wahab O, Durham B, Ozkaya N, Amoura Z, Emile JF, Haroche J.

Haematologica. 2020 Jan;105(1):e5-e8. doi: 10.3324/haematol.2019.216937. Epub 2019 May 23. No abstract available.

15.

Sequencing and curation strategies for identifying candidate glioblastoma treatments.

Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang A, Vacic V, Bergmann EA, Vogel JLM, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB.

BMC Med Genomics. 2019 Apr 25;12(1):56. doi: 10.1186/s12920-019-0500-0. Erratum in: BMC Med Genomics. 2019 Aug 2;12(1):114.

16.

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.

Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R.

Mol Cancer Ther. 2019 Jun;18(6):1149-1157. doi: 10.1158/1535-7163.MCT-18-1244. Epub 2019 Apr 23.

17.

A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease.

Diamond EL, Reiner AS, Buthorn JJ, Shuk E, Applebaum AJ, Hyman DM, Abdel-Wahab O, Rampal R, Janku F, Brewer K, Campbell J, Mao JJ, Atkinson TM, Panageas KS.

Blood Adv. 2019 Apr 9;3(7):934-938. doi: 10.1182/bloodadvances.2018030502.

18.

Efficacy of MEK inhibition in patients with histiocytic neoplasms.

Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM.

Nature. 2019 Mar;567(7749):521-524. doi: 10.1038/s41586-019-1012-y. Epub 2019 Mar 13.

19.

Letter to the Editor Regarding "National Trends for Reoperation in Older Patients with Glioblastoma".

Reiner AS, Goldman DA, Diamond EL, DeAngelis LM, Tabar V, Panageas KS.

World Neurosurg. 2018 Sep;117:466. doi: 10.1016/j.wneu.2018.04.156. No abstract available.

PMID:
30149428
20.

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.

Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O.

J Clin Invest. 2018 Aug 31;128(9):3819-3825. doi: 10.1172/JCI120787. Epub 2018 Aug 6.

21.

Value-Based Proposition for a Dedicated Interventional Pulmonology Suite: An Adaptable Business Model.

Desai NR, French KD, Diamond EJ, Kovitz KL.

Chest. 2018 Sep;154(3):699-708. doi: 10.1016/j.chest.2018.05.029. Epub 2018 Jun 1.

PMID:
29859887
22.

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.

Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, Durham BH, Braier J, Charlotte F, Donadieu J, Cohen-Aubart F, Rodriguez-Galindo C, Allen C, Whitlock JA, Weitzman S, McClain KL, Haroche J, Diamond EL.

Blood. 2018 Jun 28;131(26):2877-2890. doi: 10.1182/blood-2018-03-839753. Epub 2018 May 2. Review.

23.

Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.

Omuro A, Beal K, McNeill K, Young RJ, Thomas A, Lin X, Terziev R, Kaley TJ, DeAngelis LM, Daras M, Gavrilovic IT, Mellinghoff I, Diamond EL, McKeown A, Manne M, Caterfino A, Patel K, Bavisotto L, Gorman G, Lamson M, Gutin P, Tabar V, Chakravarty D, Chan TA, Brennan CW, Garrett-Mayer E, Karmali RA, Pentsova E.

J Clin Oncol. 2018 Jun 10;36(17):1702-1709. doi: 10.1200/JCO.2017.76.9992. Epub 2018 Apr 23.

24.

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL.

Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22. No abstract available.

25.

Associations between Mild Cognitive Dysfunction and End-of-Life Outcomes in Patients with Advanced Cancer.

Kurita K, Reid MC, Siegler EL, Diamond EL, Prigerson HG.

J Palliat Med. 2018 Apr;21(4):536-540. doi: 10.1089/jpm.2017.0385. Epub 2018 Jan 3.

26.

The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort.

Ozkaya N, Rosenblum MK, Durham BH, Pichardo JD, Abdel-Wahab O, Hameed MR, Busam KJ, Travis WD, Diamond EL, Dogan A.

Mod Pathol. 2018 Apr;31(4):581-597. doi: 10.1038/modpathol.2017.160. Epub 2017 Dec 1. Review.

27.

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM.

JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029. Erratum in: JAMA Oncol. 2019 Jan 1;5(1):122.

28.

Prognostic awareness and communication preferences among caregivers of patients with malignant glioma.

Applebaum AJ, Buda K, Kryza-Lacombe M, Buthorn JJ, Walker R, Shaffer KM, D'Agostino TA, Diamond EL.

Psychooncology. 2018 Mar;27(3):817-823. doi: 10.1002/pon.4581. Epub 2017 Dec 19.

29.

Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas.

Yeh EA, Greenberg J, Abla O, Longoni G, Diamond E, Hermiston M, Tran B, Rodriguez-Galindo C, Allen CE, McClain KL; North American Consortium for Histiocytosis.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26784. Epub 2017 Sep 25. Review.

PMID:
28944988
30.

Erdheim-Chester disease: the "targeted" revolution.

Vaglio A, Diamond EL.

Blood. 2017 Sep 14;130(11):1282-1284. doi: 10.1182/blood-2017-07-795054. No abstract available.

PMID:
28912295
31.

Managing multiple myeloma in elderly patients.

Diamond E, Lahoud OB, Landau H.

Leuk Lymphoma. 2018 Jun;59(6):1300-1311. doi: 10.1080/10428194.2017.1365859. Epub 2017 Aug 28. Review.

PMID:
28847191
32.

Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26699. Epub 2017 Jul 27.

33.

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.

Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2017 Aug 24;130(8):1007-1013. doi: 10.1182/blood-2017-01-761718. Epub 2017 Jul 5.

34.

Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma.

Diamond EL, Prigerson HG, Correa DC, Reiner A, Panageas K, Kryza-Lacombe M, Buthorn J, Neil EC, Miller AM, DeAngelis LM, Applebaum AJ.

Neuro Oncol. 2017 Oct 19;19(11):1532-1541. doi: 10.1093/neuonc/nox117.

35.

Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.

Durham BH, Roos-Weil D, Baillou C, Cohen-Aubart F, Yoshimi A, Miyara M, Papo M, Hélias-Rodzewicz Z, Terrones N, Ozkaya N, Dogan A, Rampal R, Urbain F, Le Fèvre L, Diamond EL, Park CY, Papo T, Charlotte F, Gorochov G, Taly V, Bernard OA, Amoura Z, Abdel-Wahab O, Lemoine FM, Haroche J, Emile JF.

Blood. 2017 Jul 13;130(2):176-180. doi: 10.1182/blood-2016-12-757377. Epub 2017 May 31.

36.

Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.

Milne P, Bigley V, Bacon CM, Néel A, McGovern N, Bomken S, Haniffa M, Diamond EL, Durham BH, Visser J, Hunt D, Gunawardena H, Macheta M, McClain KL, Allen C, Abdel-Wahab O, Collin M.

Blood. 2017 Jul 13;130(2):167-175. doi: 10.1182/blood-2016-12-757823. Epub 2017 May 16.

37.

Frequency and Risk Factors for Live Discharge from Hospice.

Russell D, Diamond EL, Lauder B, Dignam RR, Dowding DW, Peng TR, Prigerson HG, Bowles KH.

J Am Geriatr Soc. 2017 Aug;65(8):1726-1732. doi: 10.1111/jgs.14859. Epub 2017 Mar 13.

PMID:
28295138
38.

Existential distress among caregivers of patients with brain tumors: a review of the literature.

Applebaum AJ, Kryza-Lacombe M, Buthorn J, DeRosa A, Corner G, Diamond EL.

Neurooncol Pract. 2016 Dec;3(4):232-244. doi: 10.1093/nop/npv060. Epub 2015 Dec 8. Review.

39.

Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.

Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, You D, Gasmi B, Viale A, Chapman PB.

Oncotarget. 2016 Dec 20;7(51):85430-85436. doi: 10.18632/oncotarget.13397.

40.

Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma.

Diamond EL, Panageas KS, Dallara A, Pollock A, Applebaum AJ, Carver AC, Pentsova E, DeAngelis LM, Prigerson HG.

J Pain Symptom Manage. 2017 Feb;53(2):257-264. doi: 10.1016/j.jpainsymman.2016.09.008. Epub 2016 Nov 1.

41.

Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease.

Diamond EL, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Brody L, Arcila M, Bowers C, Fluchel M.

Blood. 2016 Oct 6;128(14):1896-1898. doi: 10.1182/blood-2016-06-725143. Epub 2016 Aug 17. No abstract available.

42.

Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease.

Diamond EL, Hatzoglou V, Patel S, Abdel-Wahab O, Rampal R, Hyman DM, Holodny AI, Raj A.

Orphanet J Rare Dis. 2016 Aug 2;11(1):109. doi: 10.1186/s13023-016-0490-3.

43.

Histiocytic neoplasms in the era of personalized genomic medicine.

Durham BH, Diamond EL, Abdel-Wahab O.

Curr Opin Hematol. 2016 Jul;23(4):416-25. doi: 10.1097/MOH.0000000000000256. Review.

44.

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Henter JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vassallo R, Weiss LM; Histiocyte Society.

Blood. 2016 Jun 2;127(22):2672-81. doi: 10.1182/blood-2016-01-690636. Epub 2016 Mar 10. Review.

45.

A randomized, double-blind, placebo-controlled trial of injected capsaicin for pain in Morton's neuroma.

Campbell CM, Diamond E, Schmidt WK, Kelly M, Allen R, Houghton W, Brady KL, Campbell JN.

Pain. 2016 Jun;157(6):1297-304. doi: 10.1097/j.pain.0000000000000544.

PMID:
26963851
46.

Developing an Interventional Pulmonary Service in a Community-Based Private Practice: A Case Study.

French KD, Desai NR, Diamond E, Kovitz KL.

Chest. 2016 Apr;149(4):1094-101. doi: 10.1016/j.chest.2015.12.025. Epub 2016 Jan 11. Review.

PMID:
26836941
47.

Cortical processing of phonetic and emotional information in speech: A cross-modal priming study.

Diamond E, Zhang Y.

Neuropsychologia. 2016 Feb;82:110-122. doi: 10.1016/j.neuropsychologia.2016.01.019. Epub 2016 Jan 18.

PMID:
26796714
48.

Nonenhancing Leptomeningeal Metastases: Imaging Characteristics and Potential Causative Factors.

Hatzoglou V, Karimi S, Diamond EL, Lis E, Krol G, Holodny AI, Young RJ.

Neurohospitalist. 2016 Jan;6(1):24-8. doi: 10.1177/1941874415591702.

49.

High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system.

Curry RC, Faivre G, Akkari L, Joyce JA, Lin O, Rosenblum M, Diamond EL, Fisher R, Omuro A.

Leuk Lymphoma. 2016 Aug;57(8):1961-4. doi: 10.3109/10428194.2015.1120867. Epub 2016 Jan 4. No abstract available.

PMID:
26727454
50.

Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas.

Arevalo-Perez J, Kebede AA, Peck KK, Diamond E, Holodny AI, Rosenblum M, Rubel J, Gaal J, Hatzoglou V.

J Neuroimaging. 2016 May;26(3):366-71. doi: 10.1111/jon.12320. Epub 2015 Dec 26.

Supplemental Content

Loading ...
Support Center